EcoR1 Capital, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001587114

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 31 positions · Total reported value $1.95B · Top-10 concentration 87.7% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.5% · 9 new · 4 cut · 6 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -3.0% · vs SPY -5.1% · Prev Value $1.95B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +0.9% · vs SPY -1.2% · Latest Value $2.11B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, EcoR1 Capital, LLC disclosed 31 equity positions with a combined reported value of $1.95B. The filing implies a focused portfolio: its ten largest positions account for 87.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ZYME ($600.45M), ANAB ($531.91M), AKTS ($155.49M). By sector, the heaviest allocations are Health Care 97.3%, Financials 0.1%. Versus the prior quarter, allocation shifted toward Health Care (+7.9pp) and away from Other (-7.9pp).

Versus the prior quarter, EcoR1 Capital, LLC opened 9 new positions, trimmed 4 and fully exited 6, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 58% of names.

The largest new positions opened in Q2 2026 were TRAX ($63.87M), FULC ($23.97M), LEGN ($23.10M).

Of the 6 positions fully exited versus the prior quarter, the largest were JAZZ ($322.61M), CRNX ($155.74M), XNCR ($26.33M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • TRAX FIRST TRACKS BIOTHERAPEUTICS · $63.87M
  • FULC FULCRUM THERAPEUTICS INC · $23.97M
  • LEGN LEGEND BIOTECH CORP · $23.10M
  • AURA AURA BIOSCIENCES INC · $11.83M
  • ODTX ODYSSEY THERAPEUTICS INC · $10.39M
  • PHVS PHARVARIS N V · $8.13M
  • NRIX NURIX THERAPEUTICS INC · $6.55M
  • ELOX ELOXX PHARMACEUTICALS INC · $5.55M

Fully Exited (vs previous quarter)

  • JAZZ JAZZ PHARMACEUTICALS PLC · prev qtr: $322.61M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $155.74M
  • XNCR XENCOR INC · prev qtr: $26.33M · history
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $16.32M
  • REPL REPLIMUNE GROUP INC · prev qtr: $7.65M
  • PRLD PRELUDE THERAPEUTICS INC · prev qtr: $3.24M
  • IBIO IBIO INC · prev qtr: $3.01M

Insider Transactions (Form 4)

Latest EcoR1 Capital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-07 Buy Atara Biotherapeutics, Inc. 507,407 $9.35 SEC filing
2026-04-20 Sell First Tracks Biotherapeutics, Inc. 4,705,575 $13.81 SEC filing

All insider transactions →

Fund Profile

EcoR1 Capital, LLC, based in San Francisco, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 31 positions worth $1.95B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-100470 (status: Approved), registered 2015-07-02
  • Regulatory AUM (Form ADV): $3.42B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds

Portfolio Structure

  • 31 positions · $1.95B reported value (Q2 2026)
  • Top 10 holdings = 87.7% of reported value
  • Largest position: ZYME (ZYMEWORKS INC) at 30.8%
  • Average position size: $62.85M

Sector Tilt

  • Health Care 97.3%
  • Financials 0.1%
  • (classified holdings cover 97% of value)

Quarterly Activity

  • Q2 2026: 9 new, 2 added, 5 reduced, 7 exited
  • 15 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund maintained a conservative stance with a slight increase in the number of positions but no significant changes in holdings' weights, suggesting a cautious approach to market fluctuations. The lack of major shifts indicates a focus on stability and steady performance. 2. Key Moves: - Added: First Tracks Biotechnology (TRAX) was introduced as a new holding, indicating a potential interest in emerging biotech companies. - Reduced: CG Oncology (CGON) saw a significant reduction of 49.0% in shares, possibly due to a reassessment of its potential or market performance. - No Change: The rest of the holdings remained constant, with no changes in share count or percentage allocation. 3. Portfolio Structure: - Passive/Active: The portfolio appears to be more passive, with a focus on holding onto existing positions rather than actively trading. - Sector Bias: The sector bias is heavily toward Health Care, with all top-10 holdings belonging to this sector, reflecting a strong belief in the long-term potential of healthcare investments. - Risk Appetite: The risk appetite seems moderate, with a balanced mix of established and emerging companies and no significant additions to high-risk sectors. 4. Per-Holding One-Liner: - ZYME: ZymeWorks Inc. is a biotechnology company focusing on the development of biocatalysts for sustainable chemistry. - ANAB: AnaptysBio Inc. is a biopharmaceutical company developing antibody-based therapies for autoimmune and inflammatory diseases. - AKTS: Akita Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer. - ETON: Eton Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of new treatments for rare and orphan diseases. - CRSP: Crispr Therapeutics AG is a biotechnology company developing gene-editing technologies for various medical applications. - ORIC: Oric Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of therapies for cancer. - TRAX: First Tracks Biotechnology (TRAX) is a biotechnology company focusing on the development of novel treatments for cancer. - LKFT: Lakefront Biotechnology NV is a biopharmaceutical company focused on the development of therapies for rare and orphan diseases. - NGNE: Neurogene Inc. is a biotechnology company focused on the development of gene therapies for neurological disorders. - CGON: CG Oncology Inc. is a biotechnology company focused on the development of therapies for cancer. 5. One-Sentence Style Summary: EcoR1 Capital maintained a conservative, healthcare-focused portfolio in Q2 2026, adding a new biotech position while reducing exposure to one stock, indicating a cautious yet optimistic outlook on the sector.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 97.3%
Financials 0.1%
Other 2.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 22.97M $600.45M 30.82%
30.82%
Hold
2 7.88M $531.91M 27.30%
27.30%
Hold
3 4.82M $155.49M 7.98%
7.98%
Hold
4 2.17M $78.62M 4.04%
4.04%
Hold
5 1.39M $75.77M 3.89%
3.89%
Hold
6 6.73M $72.87M 3.74%
3.74%
Hold
7 3.17M $63.87M 3.28%
3.28%
New
8 1.67M $49.98M 2.56%
2.56%
Hold
9 1.27M $39.98M 2.05%
2.05%
Hold
10 561.50K $39.89M 2.05%
2.05%
Reduce
11 735.00K $24.05M 1.23%
1.23%
Add
12 6.55M $23.97M 1.23%
1.23%
New
13 800.00K $23.10M 1.19%
1.19%
New
14 2.82M $21.51M 1.10%
1.10%
Hold
15 388.50K $21.45M 1.10%
1.10%
Reduce
16 789.50K $20.04M 1.03%
1.03%
Hold
17 1.55M $17.82M 0.91%
0.91%
Add
18 697.95K $13.06M 0.67%
0.67%
Reduce
19 1.67M $11.83M 0.61%
0.61%
New
20 555.55K $10.39M 0.53%
0.53%
New
21 732.61K $9.56M 0.49%
0.49%
Hold
22 235.00K $8.13M 0.42%
0.42%
New
23 1.18M $6.96M 0.36%
0.36%
Hold
24 625.00K $6.78M 0.35%
0.35%
Hold
25 270.00K $6.55M 0.34%
0.34%
New
26 330.00K $6.05M 0.31%
0.31%
Reduce
27 400.00K $5.55M 0.28%
0.28%
New
28 200.00K $2.13M 0.11%
0.11%
Hold
29 1.00M $317.70K 0.02%
0.02%
Reduce
30 4.44K $115.32K 0.01%
0.01%
Hold
31 14.70K $84.67K 0.00%
0.00%
New

FAQ

What did EcoR1 Capital, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, EcoR1 Capital, LLC reported 31 equity positions worth $1.95B in aggregate; its largest disclosed positions were ZYME ($600.45M), ANAB ($531.91M), AKTS ($155.49M).

How large is EcoR1 Capital, LLC's portfolio?

EcoR1 Capital, LLC reported $1.95B of long equity holdings across 31 positions as of 2026-Q2. Top-10 holdings account for 87.7% of reported value.

What is EcoR1 Capital, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ecor1-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →